2024
The Hierarchical Taxonomy of Psychopathology and the Search for Neurobiological Substrates of Mental Illness: A Systematic Review and Roadmap for Future Research
DeYoung C, Blain S, Latzman R, Grazioplene R, Haltigan J, Kotov R, Michelini G, Venables N, Docherty A, Goghari V, Kallen A, Martin E, Palumbo I, Patrick C, Perkins E, Shackman A, Snyder M, Tobin K. The Hierarchical Taxonomy of Psychopathology and the Search for Neurobiological Substrates of Mental Illness: A Systematic Review and Roadmap for Future Research. Journal Of Psychopathology And Clinical Science 2024, 133: 697-715. PMID: 39480338, PMCID: PMC11529694, DOI: 10.1037/abn0000903.Peer-Reviewed Original ResearchConceptsHierarchical Taxonomy of PsychopathologyTaxonomy of PsychopathologyClinical neuroscience researchHierarchical taxonomyNeuroscience researchAddictions Neuroclinical AssessmentDimensions of psychopathologyResearch Domain CriteriaDepressive symptom dimensionsHuman neuroimaging studiesTraditional psychiatric diagnosesDistress subfactorTransdiagnostic frameworkNeuroclinical AssessmentSymptom dimensionsCategorical nosologyNeurobiological substratesNeurobiological mechanismsNeuroimaging studiesPsychiatric diagnosisHiTOPInternalizing spectrumAssessment batteryPsychopathologyMental illness
2023
Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial
Ching T, Grazioplene R, Bohner C, Kichuk S, DePalmer G, D’Amico E, Eilbott J, Jankovsky A, Burke M, Hokanson J, Martins B, Witherow C, Patel P, Amoroso L, Schaer H, Pittenger C, Kelmendi B. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Frontiers In Psychiatry 2023, 14: 1178529. PMID: 37181888, PMCID: PMC10166878, DOI: 10.3389/fpsyt.2023.1178529.Peer-Reviewed Original ResearchObsessive-compulsive disorderPrimary endpointPsilocybin effectsNeural effectsRefractory obsessive-compulsive disorderNon-crossover designOpen-label doseStandard care treatmentOpen-label studyVisual analog scale ratingsTreatment of OCDEffects of psilocybinOCD symptomsInstitutional review boardYale-Brown ObsessivePrimary outcomeSingle doseCare treatmentOral psilocybinInformed consentReview boardNeurobiological mechanismsCompulsive ScalePsychological supportTrials